

| | | |
|--|-------------------------------|-------------------|
| Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary) Sheet 1 of 1 | Application Number | 10/826,058 |
| | Filing Date | April 15, 2004 |
| | First Named Inventor | Robert Falotico |
| | Group Art Unit | 1615 |
| | Examiner Name | Casey S. Hagopian |
| | Attorney Docket Number | CRD-5079USNP |
| | | |

| OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS | | | |
|---|-----------------------|--|----------------|
| Examiner's Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published | T ² |
| | | BEUTLER, E., <i>Cladribine (2-chlorodeoxyadenosine)</i> , The Lancet, Vol. 340, 1992, pp. 952-956 | |
| | | CARSON, D. et al., <i>DNA Strand Breaks, NAD Metabolism, and Programmed Cell Death</i> , Exp. Cell Research, 164, 1986, pp. 273-281 | |
| | | DEORANNE, C.F. et al., <i>Histone Deacetylases Inhibitors as Antiangiogenic Agents Altering Vascular Endothelial Growth Factor Signaling</i> , Oncogene, 21, 2002, pp. 427-436 | |
| | | LANG, R.J. et al., <i>Effects of Okadaic Acid and ATPyS on Cell Length and Ca²⁺ Channel Currents Recorded in Single Smooth Muscle Cells of the Guinea-pig Taenia Caeci</i> , Br. J. Pharmacol., 104, 1991, pp. 331-336 | |
| | | MAK, K. et al., <i>Clinical Trials to Prevent Restenosis after Percutaneous Coronary Revascularization</i> , Annals New York Academy of Sciences, 1997, pp. 255-288 | |
| | | SCHWARTZ, S.M. et al., <i>Significance of Quiescent Smooth Muscle Migration in the Injured Rat Carotid Artery</i> , Circ. Res., 56, 1985, pp. 139-145 | |
| | | SERRUYS, P.W. et al., <i>Evaluation of Ketanserlin in the Prevention of Restenosis after Percutaneous Transluminal Coronary Angioplasty. A Multicenter Randomized Double-blind Placebo-controlled Trial</i> , Circulation, 88, 1993, pp. 1588-1601 | |
| | | SERRUYS, P.W. et al., <i>Heparin-Coated Palmaz-Schatz Stents in Human Coronary Arteries: Early Outcome of the Benestent-II Pilot Study</i> , Circulation, Vol. 93(3), 1996, pp. 412-422 | |
| | | SETO, S. et al., <i>Mechanism of Deoxyadenosine and 2-Chlorodeoxyadenosine Toxicity to Nondividing Human Lymphocytes</i> , J. Clin. Invest., Vol. 75, 1985, pp. 377-383 | |
| | | WILEY, J., <i>Fluorocarbon Elastomers</i> , Modern Fluoropolymers, Wiley Series in Polymer Science, 1997, pp. 71-90 | |
| | | WOO, S.H., <i>Structurally Simple Trichostatin A-like Straight Chain Hydroxamates as Potent Histone Deacetylase Inhibitors</i> , J. of Medicinal Chemistry, 45(13), 2002, pp. 2877-2885 | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.
 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.